Across the recent three months, 4 analysts have shared their insights on Viridian Therapeutics (NASDAQ:VRDN), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
1
0
0
0
Last 30D
1
0
0
0
0
1M Ago
2
1
0
0
0
2M Ago
0
0
0
0
0
3M Ago
0
0
0
0
0
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $34.25, a high estimate of $40.00, and a low estimate of $30.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.72%.
Exploring Analyst Ratings: An In-Depth Overview
In examining recent analyst actions, we gain insights into how financial experts perceive Viridian Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Serge Belanger
Needham
Maintains
Buy
$30.00
$30.00
Douglas Tsao
HC Wainwright & Co.
Maintains
Buy
$37.00
-
Laura Chico
Wedbush
Raises
Outperform
$40.00
$39.00
Serge Belanger
Needham
Maintains
Buy
$30.00
-
Key Insights:
Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Viridian Therapeutics. ...Full story available on Benzinga.com
Benzinga
